Este artículo solo puede leerse en
pdf
References
[1]
M. Anguita, A. Fernández-Ortiz, F. Worner, A. Alonso, A. Cequier, J. Comín, et al.
La Sociedad Española de Cardiología y las guías de práctica clínica de la SEC: hacia una nueva orientación.
Rev Esp Cardiol., (2011), 64 pp. 795-796
[2]
P.M. Elliott, A. Anastasakis, M.A. Borger, M. Borggrefe, F. Cecchi, P. Charron, et al.
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.
Eur Heart J., (2014), 35 pp. 2733-2779
[3]
B.J. Maron, W.J. McKenna, G.K. Danielson, L.J. Kappenberger, H.J. Kuhn, C.E. Seidman, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy.
Eur Heart J., (2003), 24 pp. 1965-1991
[4]
B.J. Gersh, B.J. Maron, R.O. Bonow, J.A. Dearani, M.A. Fifer, M.S. Link, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.
J Am Coll Cardiol., (2011), 58 pp. e212-e260
[5]
Centros, Servicios y Unidades de Referencia del Sistema Nacional de Salud [Cited 28 Sept 2014]. Available at: https://www.msssi.gob.es/profesionales/CentrosDeReferencia/CentrosCSUR.htm.
[6]
W.J. McKenna, P. Spirito, M. Desnos, O. Dubourg, M. Komajda.
Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families.
Heart., (1997), 77 pp. 130-132
[7]
L. Monserrat, P.M. Elliott, J.R. Gimeno, S. Sharma, M. Penas-Lado, W.J. McKenna.
Non- sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
J Am Coll Cardiol., (2003), 42 pp. 873-879
[8]
P.M. Elliott, J.R. Gimeno, M.T. Tomé, J. Shah, D. Ward, R. Thaman, et al.
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.
Eur Heart J., (2006), 27 pp. 1933-1941
[9]
C. O’Mahony, F. Jichi, M. Pavlou, L. Monserrat, A. Anastasakis, C. Rapezzi, et al.
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
Eur Heart J., (2014), 35 pp. 2010-2020
[10]
A. D’Andrea, P. Caso, S. Severino, S. Cuomo, G. Capozzi, P. Calabrò, et al.
Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy.
Eur Heart J., (2006), 27 pp. 1311-1318
[11]
A. D’Andrea, P. Caso, S. Cuomo, G. Salerno, R. Scarafile, C. Mita, et al.
Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes.
Br J Sports Med., (2006), 40 pp. 244-250
[12]
R.H. Chan, B.J. Maron, I. Olivotto, PencinaMJ, G.E. Assenza, T. Haas, et al.
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Circulation., (2014), 130 pp. 484-495
[13]
W.J. McKenna, S.F. Nagueh.
Cardiac magnetic resonance imaging and sudden death risk in patients with hypertrophic cardiomyopathy.
Circulation., (2014), 130 pp. 455-457
[14]
M. Cobo-Marcos, S. Cuenca, J.M. Gámez Martínez, B. Bornstein, T. Ripoll Vera, P. Garcia- Pavia.
Usefulness of genetic testing for hypertrophic cardiomyopathy in real- world practice.
Rev Esp Cardiol., (2013), 66 pp. 746-747
[15]
P. Charron, M. Arad, E. Arbustini, C. Basso, Z. Bilinska, P. Elliott, et al.
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur Heart J., (2010), 31 pp. 2715-2726
[16]
J.M. De la Torre Hernandez, M. Masotti Centol, P. Lerena Saenz, A. Sánchez Recalde, F. Gimeno de Carlos, P. Piñón Esteban, et al.
Eficacia y seguridad a más de 10 años de la ablación septal percutánea en la miocardiopatía hipertrófica obstructiva.
Rev Esp Cardiol., (2014), 67 pp. 353-358
[17]
McMurray JJV, Adamopoulos S, Stefan D. Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. Eur Heart J. 2012; doi:10.1093/eurheartj/ehs104.
[18]
D.P. Rogers, S. Marazia, A.W. Chow, P.D. Lambiase, M.D. Lowe, M. Frenneaux, et al.
Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy.
Eur J Heart Fail., (2008), 10 pp. 507-513
[19]
O.P. Guttmann, M.S. Rahman, C. O’Mahony, A. Anastasakis, P.M. Elliott.
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
Heart., (2014), 100 pp. 465-472
[20]
C. O’Mahony, P.M. Elliott.
Prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Heart., (2014), 100 pp. 254-260
[21]
P.A. Vriesendorp, A.F.L. Schinkel, M. Liebregts, R. Willems, F.J. Ten Cate, J. Van Cleemput, et al.
Independent validation of the novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD).
Eur Heart J., (2014), 35 pp. 210
[22]
European Society of Cardiology. HCM Risk-SCD Calculator. 2014. Available at: www.doc2do.com/hcm/webHCM.html.
[23]
A.E. Buxton, K.L. Lee, J.D. Fisher, M.E. Josephson, E.N. Prystowsky, G. Hafley.
A randomized study of the prevention of sudden death in patients with coronary artery disease.
Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med., (1999), 341 pp. 1882-1890
[24]
A.J. Moss, W.J. Hall, D.S. Cannom, J.P. Daubert, S.L. Higgins, H. Klein, et al.
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.
Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med., (1996), 335 pp. 1933-1940
[25]
A.J. Moss, W. Zareba, W.J. Hall, H. Klein, D.J. Wilber, D.S. Cannom, et al.
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
N Engl J Med., (2002), 346 pp. 877-883
[26]
I. Goldenberg, J. Gillespie, A.J. Moss, W.J. Hall, H. Klein, S. McNitt, et al.
Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II.
Long- term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation., (2010), 122 pp. 1265-1271
[27]
The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias. N Engl J Med. 1997;337:1576-84.
[28]
BardyGH, K.L. Lee, D.B. Mark, J.E. Poole, D.L. Packer, R. Boineau, et al.
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
N Engl J Med., (2005), 352 pp. 225-237
[29]
M.A. Pfeffer, E. Braunwald, L.A. Moyé, L. Basta, E.J. Brown Jr., T.E. Cuddy, et al.
the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial.
N Engl J Med., (1992), 327 pp. 669-677
[30]
The MERIT investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
[31]
P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, et al.
JUPITER Study Group.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med., (2008), 359 pp. 2195-2207
[32]
A. Vahanian, O. Alfieri, F. Andreotti, M.J. Antunes, G. Barón-Esquivias, H. Baumgartner, et al.
Guidelines on the Management of Valvular Heart disease (Version 2012).
Eur Heart J., (2012), 33 pp. 2451-2496
Copyright ©
2014. Sociedad Española de Cardiología